These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21590790)

  • 1. Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.
    Polley MY
    Stat Med; 2011 Jul; 30(17):2130-43. PubMed ID: 21590790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples.
    van Werkhoven E; Hinsley S; Frangou E; Holmes J; de Haan R; Hawkins M; Brown S; Love SB
    BMC Med Res Methodol; 2020 Jun; 20(1):162. PubMed ID: 32571298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method.
    North B; Kocher HM; Sasieni P
    BMC Cancer; 2019 Jun; 19(1):632. PubMed ID: 31242873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring late-onset toxicities in phase I trials using predicted risks.
    Bekele BN; Ji Y; Shen Y; Thall PF
    Biostatistics; 2008 Jul; 9(3):442-57. PubMed ID: 18084008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rolling continual reassessment method with overdose control: An efficient and safe dose escalation design.
    Zhu J; Sabanés Bové D; Liao Z; Beyer U; Yung G; Sarkar S
    Contemp Clin Trials; 2021 Aug; 107():106436. PubMed ID: 34000410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the time-to-event continual reassessment method in the presence of partial orders.
    Wages NA; Conaway MR; O'Quigley J
    Stat Med; 2013 Jan; 32(1):131-41. PubMed ID: 22806898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
    Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
    Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The superiority of the time-to-event continual reassessment method to the rolling six design in pediatric oncology Phase I trials.
    Zhao L; Lee J; Mody R; Braun TM
    Clin Trials; 2011 Aug; 8(4):361-9. PubMed ID: 21610004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential designs for phase I clinical trials with late-onset toxicities.
    Cheung YK; Chappell R
    Biometrics; 2000 Dec; 56(4):1177-82. PubMed ID: 11129476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.
    Yuan Y; Lin R; Li D; Nie L; Warren KE
    Clin Cancer Res; 2018 Oct; 24(20):4921-4930. PubMed ID: 29769209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining a maximum tolerated cumulative dose: dose reassignment within the TITE-CRM.
    Braun TM; Levine JE; Ferrara JL
    Control Clin Trials; 2003 Dec; 24(6):669-81. PubMed ID: 14662273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
    James GD; Symeonides S; Marshall J; Young J; Clack G
    BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generalizing the TITE-CRM to adapt for early- and late-onset toxicities.
    Braun TM
    Stat Med; 2006 Jun; 25(12):2071-83. PubMed ID: 16217853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials.
    Dinart D; Fraisse J; Tosi D; Mauguen A; Touraine C; Gourgou S; Le Deley MC; Bellera C; Mollevi C
    BMC Med Inform Decis Mak; 2020 Jun; 20(1):134. PubMed ID: 32580715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to design a dose-finding study using the continual reassessment method.
    Wheeler GM; Mander AP; Bedding A; Brock K; Cornelius V; Grieve AP; Jaki T; Love SB; Odondi L; Weir CJ; Yap C; Bond SJ
    BMC Med Res Methodol; 2019 Jan; 19(1):18. PubMed ID: 30658575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials.
    Ishizuka N; Ohashi Y
    Stat Med; 2001 Sep 15-30; 20(17-18):2661-81. PubMed ID: 11523075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial.
    Huang B; Kuan PF
    Biom J; 2014 Nov; 56(6):933-46. PubMed ID: 24895140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The continual reassessment method for dose-finding studies: a tutorial.
    Garrett-Mayer E
    Clin Trials; 2006; 3(1):57-71. PubMed ID: 16539090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating patient-reported outcomes in dose-finding clinical trials with continuous patient enrollment.
    Andrillon A; Biard L; Lee SM
    J Biopharm Stat; 2023 Jul; ():1-12. PubMed ID: 37496233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.